Using a propensity score matching analysis, Nagaoki et al. [48] evaluated the cumulative incidence of HCC in 154 HCV patients with chronic hepatitis or cirrhosis treated with daclatasvir/asunaprevir compared with a historical cohort of 244 patients treated with IFN-based regimens. This evidence concerns the gene IFNA1 and chronic hepatitis.